Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Park JC, Berz D, Sharma MR, Malhotra J, Tolcher AW, Hauke RJ, Call JA, Hamm JT, Sanborn RE, Haas NB, Tsai F, Adkins DR, Camidge DR, Spira AI, Senne L, Kalabus J, O'Neill B, Kinkead H, Garcia J, Massarelli E. Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors. Cancer Res Commun. 2026 02 01; 6(2):374-382.